Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: A meta-analysis

Molecular Biology Reports

Volumn 40, Issue 1, 2013, Pages 617-623

  Shi, Mumu ^a,b   Yu, Bo ^a   Gao, Hongguo ^c   Mu, Jingwen ^a,b   Ji, Changwei ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Biopharmaceutical Institute   (China)

^c Daqing Oilfield General Hospital   (China)

Author keywords

Colorectal cancer; Matrix metalloproteinase 2; Meta analysis; Prognosis

Indexed keywords

GELATINASE A;

CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; ENZYME ACTIVITY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUBLISHING; REVIEW; SENSITIVITY ANALYSIS;

COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; ODDS RATIO; PROGNOSIS; PUBLICATION BIAS;

EID: 84871340296     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2100-3     Document Type: Review

References (37)

1. Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030-1047
2. Lieberman DA (2009) Clinical practice. Screening for colorectal cancer. N Engl J Med 361:1179-1187
3. Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101-117
4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:163-176
5. Escaff S, Fernandez JM, Gonzalez LO et al (2011) Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer. J Cancer Res Clin Oncol 137:551-555
6. Leeman MF, Curran S, Murray GI (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201:528-534
7. Langers AM, Verspaget HW, Hawinkels LJ et al (2012) MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer. doi: 10.1038/bjc.2012.80
8. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012
9. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834
10. Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16
11. Maxwell L, Santesso N, Tugwell PS et al (2006) Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol 33:2304-2311
12. Millett GA, Flores SA, Marks G et al (2008) Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 300:1674-1684
13. Wells G, Shea B, O'Connell D et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Ottawa Health Research Institute Web site. http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp. Accessed 26 June 2012
14. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
16. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
17. Thompson SG, Higgins J (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559-1573
18. Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15-17
19. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
20. Hilska M, Roberts PJ, Collan YU et al (2007) Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121:714-723
21. Li M, Li JY, Zhao AL et al (2007) Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1. Dis Colon Rectum 50:1887-1898
22. Sundov Z, Tomic S, Vilovic K et al (2008) Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke's B colon cancer. Croat Med J 49:636-642
23. Zhou ZG, Wu XJ, Li LR et al (2011) A multivariate analysis of prognostic determinants for stages II and III colorectal cancer in 141 patients. Chin Med J (Engl) 124:2132-2135
24. Langers AM, Sier CF, Hawinkels LJ et al (2008) MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer 98:1820-1823
25. Unsal D, Akyurek N, Uner A et al (2008) Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol 31:55-63
26. Dong W, Li H, Zhang Y et al (2011) Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai) 43:840-848
27. Cho YB, Lee WY, Song SY et al (2007) Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 38:1603-1610
28. Hong SW, Kang YK, Lee B et al (2011) Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 27:133-139
29. Lu GJ, Cao XC, Lu FL (2009) The correlation between of matrixmetalloproteinase2 and rectal cancer. J Int Oncol 36:554-557
30. Peng ZH, Wan DS, Li LR et al (2011) Expression of COX-2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance. Hepatogastroenterology 58:369-376
31. Schwandner O, Schlamp A, Broll R et al (2007) Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 22:127-136
32. Gonzalez LO, Gonzalez-Reyes S, Junquera S et al (2010) Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events. J Cancer Res Clin Oncol 136:1313-1321
33. Uhlmann ME, Georgieva M, Sill M et al (2012) Prognostic value of tumor progression-related gene expression in colorectal cancer patients. J Cancer Res Clin Oncol. doi: 10.1007/s00432-012-1238-7
34. Nelson AR, Fingleton B, Rothenberg ML et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135-1149
35. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174
36. Watanabe T, Kobunai T, Yamamoto Y et al (2012) Chromosomal instability (CIN) phenotype, CIN high or CIN low predicts survival for colorectal cancer. J Clin Oncol. doi: 10.1200/JCO.2011.38.6490
37. Hahn N, Heiden M, Seitz R et al (2012) Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion. J Cancer Res Clin Oncol 138:695-703